Navigation Links
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Date:10/23/2007

SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug candidates, CT-47613 and CT-47609, kill tumors refractory to currently marketed platinum agents carboplatin, cisplatin and oxaliplatin. These compounds could enter human clinical trials in late 2008.

"Bis-platinates represent a promising new class of platinum-based chemotherapy drugs with a potential broad spectrum of anti-tumor activity. Anti-cancer drugs containing platinum are a cornerstone therapy for a wide range of tumor types including ovarian, testicular, colorectal, head and neck, and lung cancer," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "These bis-platinates, unlike the currently approved platinum compounds, contain two platinum atoms and work by binding to and damaging both strands of DNA making it much more difficult for cancer cells to repair the damage. The preclinical studies presented at this meeting suggest these compounds are substantially more active than the existing monoplatinates -- especially against platinum-resistant tumors. These agents could represent a significant advance in the treatment of a wide variety of cancers."

Novel bisplatinum complexes characterized by an improved in vitro plasma protein binding and in vivo efficacy on xenograft models (Abstract A267)

Scientists from CTI-Europe presented data on two novel bis-platinum complexes, CT-47613 and CT-47609. When tested in animal models of ovarian cancer and colon cancer, the bis-platinates were significantly more potent than the two most commonly used platinum based chemotherapy drugs, carboplatin and cisplatin and oxaliplatin. Importantly these agents demonstrated potent anti-tumor activity in tumors with either acquired or intrinsic resistance to cisplatin or carboplatin, representing the first such class of binuclear platinum based
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Proove Biosciences , ... International Spine Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ... With a focus on evidence-based research and clinical application, the event gathered industry ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal Health ... animal health companies to hear from animal health companies with the newest technology. ... licensing agreements or distribution contracts. This meeting is one of the only ...
(Date:8/27/2015)... PARK, Calif. , Aug. 27, 2015  Asterias ... in the emerging field of regenerative medicine, today announced ... investor conferences in the month of September.  ... will present at Rodman & Renshaw,s 17th Annual Global ... ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... product choices to a manageable shortlist of bench and floor scales and terminals. ... fit best with the customer’s industry and application. , Side-by-side product comparisons ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2
... Verenium Corporation (Nasdaq: VRNM ), ... high-performance industrial enzyme solutions, today announced that it ... a high performance enzyme for the saccharification of ...  The DELTAZYM® GA L-E5 enzyme has demonstrated high ...
... a three-hospital health system providing care to ... management system provided by Surgical Information Systems ... into the hospitals, existing Siemens Soarian® system ... and drive business results. (Logo: ...
... MISSISSAUGA, ON, Sept. 29 /PRNewswire-FirstCall/ - YM BioSciences ... Pulmokine Inc. (Slingerlands, New York), a licensee of ... awarded two National Institutes of Health (NIH) Small ... more than US$650,000, are Phase I awards to ...
Cached Biology Technology:Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production 2Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production 3Susquehanna Health Selects Perioperative and Anesthesia Automation Solution from Surgical Information Systems 2Susquehanna Health Selects Perioperative and Anesthesia Automation Solution from Surgical Information Systems 3Susquehanna Health Selects Perioperative and Anesthesia Automation Solution from Surgical Information Systems 4YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension 2YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension 3
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... . , A tip about a folk ... off bugs has led to the discovery of insect-repelling ... identified components of Jatropha curcas seed oil ... Agricultural Research Service (ARS) Natural Products Utilization Research Unit ...
... Approximately one-third of Americans take a daily multivitamin, but little ... Now, new research from Brigham and Women,s Hospital (BWH) ... of cardiovascular disease in men. A similar BWH study, ... man,s risk of cancer by 8 percent. The cardiovascular ...
... move their facial whiskers back and forth about eight times ... acquire this sense? And if they can, what could understanding ... about how humans normally sense? At the Weizmann Institute, researchers ... of blindfolded volunteers and asking them to carry out a ...
Cached Biology News:Daily multivitamin use does not reduce cardiovascular disease risk in men 2Learning a new sense 2Learning a new sense 3
... catalyzes the degradation of single-stranded DNA and ... While the nuclease prefers ssDNA over dsDNA ... enzyme degrades double-stranded DNA from both ends ... for transcript mapping studies (3,4), for flushing ...
... The S.c. EasyComp Transformation Kit is ... Saccharomyces cerevisiae cells. Advantages over commonly ... formation or LiCl methods include:- Cells can ... 30 minutes - Competent cell preparation and ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
...
Biology Products: